Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Liabilities and Shareholders Equity (2017 - 2025)

Protagonist Therapeutics' Liabilities and Shareholders Equity history spans 9 years, with the latest figure at $668.2 million for Q4 2025.

  • For Q4 2025, Liabilities and Shareholders Equity fell 10.28% year-over-year to $668.2 million; the TTM value through Dec 2025 reached $2.8 billion, up 9.16%, while the annual FY2025 figure was $668.2 million, 10.28% down from the prior year.
  • Liabilities and Shareholders Equity for Q4 2025 was $668.2 million at Protagonist Therapeutics, down from $701.7 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $744.7 million in Q4 2024 and bottomed at $239.9 million in Q1 2023.
  • The 5-year median for Liabilities and Shareholders Equity is $365.6 million (2021), against an average of $464.1 million.
  • The largest annual shift saw Liabilities and Shareholders Equity tumbled 31.13% in 2023 before it soared 162.35% in 2024.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $347.7 million in 2021, then dropped by 28.69% to $247.9 million in 2022, then surged by 44.38% to $358.0 million in 2023, then soared by 108.05% to $744.7 million in 2024, then decreased by 10.28% to $668.2 million in 2025.
  • Per Business Quant, the three most recent readings for PTGX's Liabilities and Shareholders Equity are $668.2 million (Q4 2025), $701.7 million (Q3 2025), and $718.0 million (Q2 2025).